Clinical Trials
21
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Conditions
- UC - Ulcerative ColitisModerately to Severely Active Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT07035041
- Locations
- 🇨🇳
Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 640
- Registration Number
- NCT06954961
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 161
- Registration Number
- NCT06278350
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT06233916
- Locations
- 🇨🇳
beijing Gobroad Boren Hospital, Beijing, China
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT06105255
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.